Metlife (MET) Cash & Equivalents (2009 - 2026)

Metlife has reported Cash & Equivalents for 18 years, with the latest figure at $19.3 billion in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 12.97% year-over-year to $19.3 billion in Q2 2026; TTM through Jun 2026 was $19.3 billion, a 12.97% decrease from a year earlier, with the FY2025 full-year figure at $22.0 billion, up 9.79% from the prior year.
• Cash & Equivalents was $19.3 billion for Q2 2026 at Metlife, down from $22.7 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $23.5 billion in Q1 2022, with the low at $14.9 billion in Q3 2023.
• Average Cash & Equivalents over 5 years is $20.3 billion, with a median of $20.6 billion recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 32.83% in 2023, then surged 45.96% in 2024.
• Over 5 years, Cash & Equivalents stood at $20.2 billion in 2022, then climbed by 2.2% to $20.6 billion in 2023, then slipped by 2.77% to $20.1 billion in 2024, then rose by 9.79% to $22.0 billion in 2025, then slipped by 12.4% to $19.3 billion in 2026.
• The last three Cash & Equivalents figures came in at $19.3 billion (Q2 2026), $22.7 billion (Q1 2026), and $22.0 billion (Q4 2025), per Business Quant data.